Madrigal Pharmaceuticals has secured accelerated approval from the FDA for its drug Resmetirom, which treats nonalcoholic steatohepatitis (NASH), now known as metabolic dysfunction-associated ...
The dash for MASH is gaining momentum, with Roche AG acquiring 89bio Inc. and its phase III FGF21 analogue, pegozafermin, for treating metabolic dysfunction-associated steatohepatitis, in a deal worth ...
Main Street Lorain will present its annual Monster Mash Dash along with other activities Oct. 4. The run starts off at 9:45 a.m., launching a costumed crowd of runners, walkers and even four-legged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results